Patents Assigned to Ludwig Institute for Cancer Research Ltd.
-
Patent number: 9200047Abstract: The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-2 gene.Type: GrantFiled: February 16, 2011Date of Patent: December 1, 2015Assignee: Ludwig Institute for Cancer Research, Ltd.Inventors: Danila Valmori, Maha Ayyoub
-
Patent number: 9072798Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: GrantFiled: February 17, 2010Date of Patent: July 7, 2015Assignee: Ludwig Institute for Cancer Research LTD.Inventors: Gerd Ritter, Anne Murray, George Mark, Christoph Renner
-
Patent number: 9045533Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: GrantFiled: September 26, 2013Date of Patent: June 2, 2015Assignees: Ludwig Institute for Cancer Research Ltd, Institute for Molecular Biology and Genetics National Academy of Science of Ukraine, Sloan Kettering Cancer InstituteInventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Patent number: 9023356Abstract: The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described.Type: GrantFiled: March 14, 2008Date of Patent: May 5, 2015Assignees: Ludwig Institute for Cancer Research Ltd, The Regents of the University of CaliforniaInventors: Terrance Grant Johns, Webster Cavenee, Frank Furnari, Andrew Scott
-
Patent number: 8999342Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.Type: GrantFiled: October 1, 2010Date of Patent: April 7, 2015Assignee: Ludwig Institute for Cancer Research, Ltd.Inventors: Christoph Renner, Eliane Fischer, Stefan Bauer, Thomas Wüest
-
Publication number: 20140377268Abstract: Disclosed herein are methods to inhibit cleavage of a type I receptor of transforming growth factor beta (T?RI) and reduce cancer cell invasiveness/metastasis, and agents and pharmaceutical compositions for use in these methods. Also disclosed herein are methods for identifying agents that inhibit cleavage of T?RI and methods for diagnosing and/or prognosing cancer based on nuclear localization of a intracellular domain of T?RI, which is a product of T?RI cleavage.Type: ApplicationFiled: March 13, 2012Publication date: December 25, 2014Applicant: Ludwig Institute for Cancer Research Ltd.Inventors: Marene Inga-Britt Landstrom, Yabing Mu, Reshma Sundar, Noopur Thakur, Shyam Kumar Gudey, Maria Ekman, Carl-Henrik Heldin
-
Publication number: 20140322130Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: March 26, 2014Publication date: October 30, 2014Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Andrew M. Scott, Terrance Grant Johns, George Mark, Anne Murray, Christoph Renner, Gerd Ritter
-
Patent number: 8802631Abstract: The invention is based on the discovery that STM/Hop promotes proliferation of human glioblastoma-derived cells but not of normal astrocytes and that the proliferation requires the binding of STM/Hop to PrPc. The invention is directed to methods for treating cancer which rely on interfering with the Hop-PrPc interaction and to peptides, and antibodies raised against the peptides, which directly provide that interference. The invention is further based on the discovery that STI1230-245 peptide and its human homologue Hop23o-245 provide the desired interference with the STI1/Hop-PrPc interaction and inhibit the STI 1/Hop-induced proliferation of glioma and glioblastoma cells. The invention is thus further directed to methods of treating cancer that employ these peptides and functional derivatives thereof, and antibodies directed to the peptides and derivatives. The invention is further directed to means of treating cancer which involve reducing the effective amount of Hop or reducing the expression of Hop.Type: GrantFiled: September 17, 2008Date of Patent: August 12, 2014Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Rafael Bierig Erlich, Luciana Chiarini, Vilma R. Martins, Rafael Linden, Vivaldo Moura Neto
-
Publication number: 20140140998Abstract: Disclosed herein are methods to inhibit cleavage of a type I receptor of transforming growth factor beta (T?RI) and reduce cancer cell invasiveness/metastasis, and agents and pharmaceutical compositions for use in these methods. Also disclosed herein are methods for identifying agents that inhibit cleavage of T?RI and methods for diagnosing and/or prognosing cancer based on nuclear localization of a intracellular domain of T?RI, which is a product of T?RI cleavage.Type: ApplicationFiled: March 13, 2012Publication date: May 22, 2014Applicant: Ludwig Institute for Cancer Research Ltd.Inventors: Marene Inga-Britt Landstrom, Yabing Mu, Reshma Sundar, Noopur Thakur, Shyam Kumar Gudey, Maria Ekman, Carl-Henrik Heldin
-
Patent number: 8679765Abstract: The invention relates, at least in part, to the identification of paratarg as a paraprotein target in various malignant and non-malignant gammopathies, which can be used in the diagnosis and treatment of either.Type: GrantFiled: January 22, 2010Date of Patent: March 25, 2014Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Klaus-Dieter Preuss, Michael Pfreundschuh
-
Publication number: 20140050780Abstract: The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.Type: ApplicationFiled: December 22, 2011Publication date: February 20, 2014Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Vincenzo Cerundolo, Simon Eastman
-
Patent number: 8652473Abstract: The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.Type: GrantFiled: January 29, 2010Date of Patent: February 18, 2014Assignees: Ludwig Institute for Cancer Research Ltd., Massachusetts Institute for Technology, Commonwealth Scientific and Industrial Research OrganizationInventors: Terrance Grant Johns, Andrew Mark Scott, Antony Wilks Burgess, Lloyd J. Old, Timothy E. Adams, K. Dane Wittrup, Ginger Chao, Peter Anthony Hoyne
-
Patent number: 8603474Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: GrantFiled: January 29, 2009Date of Patent: December 10, 2013Assignees: Ludwig Institute for Cancer Research, Ltd., Institute of Molecular Biology and Genetics National Academy of Science of Ukraine, Sloan-Kettering Institute for Cancer ResearchInventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Publication number: 20130302277Abstract: The present invention relates generally to the field of cancer therapy. More particularly, the present invention provides a method for the treatment of gastrointestinal-type cancers and therapeutic agents useful for same.Type: ApplicationFiled: July 30, 2013Publication date: November 14, 2013Applicants: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD., CSL LIMITEDInventors: Brendan J. JENKINS, Tracy Lynn PUTOCZKI, Matthias ERNST, Andrew JARNICKI, Brent MCKENZIE
-
Publication number: 20130289253Abstract: Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized.Type: ApplicationFiled: September 30, 2011Publication date: October 31, 2013Applicant: Ludwig Institute for Cancer Research Ltd.Inventors: Immanuel F. Luescher, Julien Schmidt, Philippe Guillaume, Danijel Dojcinovic
-
Publication number: 20130224249Abstract: Recombinant, attenuated parasites are transformed or transfected with nucleic acid molecules which provoke an immunostimulatory and protective response in subjects. Preferably, the parasite is Trypanosoma cruzi, especially strain CL-14, and the transforming nucleic acid molecule encodes for a cancer testis antigen, such as NY-ESO-1.Type: ApplicationFiled: September 1, 2011Publication date: August 29, 2013Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Bruno Galvao Filho, Ricardo Tostes Gazzinelli, Caroline Junqueira Giusta, Santuza Maria Ribeiro Teixeira
-
Patent number: 8519109Abstract: Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.Type: GrantFiled: February 3, 2009Date of Patent: August 27, 2013Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Lan-Qing Huang, Aline van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon-Falleur
-
Patent number: 8518888Abstract: The present invention relates generally to the field of cancer therapy. More particularly, the present invention provides a method for the treatment of gastrointestinal-type cancers and therapeutic agents useful for same.Type: GrantFiled: October 14, 2009Date of Patent: August 27, 2013Assignees: CSL Limited, Ludwig Institute for Cancer Research Ltd.Inventors: Brendan J. Jenkins, Tracy Lynn Putoczki, Matthias Ernst, Andrew Jarnicki, Brent McKenzie
-
Patent number: 8420791Abstract: The present invention relates to the treatment, diagnosis, and prophylaxis of cancer based on the expression of foxp3.Type: GrantFiled: November 27, 2007Date of Patent: April 16, 2013Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Lisa Michelle Ebert, Weisan Chen, Jonathan S. Cebon, Ian Davis
-
Publication number: 20130029358Abstract: Immunostimulatory NY-ESO-1 epitopes recognized by MHC-DRB3*0202 (DR52b) or DRB1*0101 (DR1) restricted T cells are described. Methods for their use in diagnostic and therapeutic approaches are also provided. Further, methods for the generation and isolation of MHC class II molecules, either “empty” or peptide-loaded, are provided. Methods for the assembly of MHC class II multimers, for example, tetramers, are also provided. Methods for the detection of T cells binding to specific peptide-loaded MHC class II molecules are also described herein.Type: ApplicationFiled: October 1, 2010Publication date: January 31, 2013Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Danila Valmori, Maha Ayyoub, Immanuel F. Luescher, Danijel Dojcinovic